| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2024―Jun―23 |
The impact of tuberculosis on the development of immune response to SARS-CoV-2 |
GS Shepelkova, NA Chernyh, VK Kosiakova, SS Sadovnikova, A Ergeshov, VV Yeremeev |
| 2 |
[GO] |
2024―Jan―17 |
Altered circadian expression of cytokines in blood of patients with essential hypertension following COVID-19 |
OA Radaeva, AS Simbirtsev, YuA Kostina, MS Iskandiarova, EV Negodnova, SV Mashnina, et al. (+3) VV Yeremeev, KA Krasnoglazova, IO Babushkin |
| 3 |
[GO] |
2023―Feb―28 |
Single-domain antibody for binding the conserved epitope in the SARS-CoV-2 spike protein receptor-binding domain |
PO Vorobyev, SV Tillib |
| 4 |
[GO] |
2023―Jan―12 |
Efficacy of favipiravir and molnupiravir against novel SARS-CoV-2 variants in vitro and in vivo |
AE Siniavin, LI Russu, DV Vasina, EV Shidlovskaya, NA Kuznetsova, VA Guschin, AL Gintsburg |
| 5 |
[GO] |
2023―Jan―11 |
The rs17713054 and rs1800629 polymorphisms of genes LZTFL1 and TNF are associated with COVID-19 severity |
AA Traspov, MM Minashkin, SV Poyarkov, AG Komarov, IA Shtinova, GI Speshilov, et al. (+3) IA Karbyshev, NV Pozdniakova, MA Godkov |
| 6 |
[GO] |
2023―Jan―10 |
Drug design strategies for the treatment of coronavirus infection |
SS Terekhov, VI Shmygarev, KV Purtov, IV Smirnov, IV Yampolsky, AS Tsarkova |
| 7 |
[GO] |
2022―Nov―01 |
Antiphospholipid antibodies and outcomes of assisted reproductive technology programs in patients with a history of COVID-19 |
DM Ermakova, NV Dolgushina, IV Menzhinskaya, NA Lomova, VV Vtorushina |
| 8 |
[GO] |
2022―Oct―25 |
Geographic distribution of the LZTFL1 SNP markers associated with severe COVID-19 in Russia and worldwide |
EV Balanovska, IO Gorin, VS Petrushenko, DK Chernevskiy, SM Koshel, II Temirbulatov, et al. (+2) VYu Pylev, AT Agdzhoyan |
| 9 |
[GO] |
2022―Jun―06 |
Intermembrane oligomerization of SARS-CoV-2 M-protein: possible role in viral budding |
EL Sokolinskaya, LV Putlyaeva, AA Gorshkova, KA Lukyanov |
| 10 |
[GO] |
2022―May―18 |
Altered amino acid profiles of the “mother-fetus” system in COVID-19 |
NA Lomova, VV Chagovets, EL Dolgopolova, AV Novoselova, UL Petrova, RG Shmakov, VE Frankevich |
| 11 |
[GO] |
2022―Apr―22 |
Effects of COVID-19 vector vaccine on autoantibody profile in reproductive age women |
AA Dovgan, YuS Drapkina, NV Dolgushina, IV Menzhinskaya, LV Krechetova, GT Sukhikh |
| 12 |
[GO] |
2022―Apr―18 |
Experience of tocilizumab in hospital patients with moderate COVID-19 |
OA Burgasova, SV Dolinniy, VB Tetova, DA Ogarkova, MA Odnoralov, VV Bakalin, et al. (+3) SV Smetanina, NA Antipyat, MV Taranova |
| 13 |
[GO] |
2022―Feb―20 |
Gut microbiota alterations and their relationship to the disease severity and some cytokine profile indicators in patients with COVID-19 |
LN Gumenyuk, MV Golod, NV Silaeva, LE Sorokina, SS Ilyasov, NA Androschyuk, et al. (+3) OR Krivoshapko, AM Velilyaev, LN Asanova |
| 14 |
[GO] |
2022―Feb―20 |
Dynamic changes in the concentration of anti-SARS-CoV-2 antibodies within 12 months after recovery from COVID-19 |
NA Mayanskiy, EA Brzhozovskaya, SS Stoyanova, AV Frolkov, YuS Lebedin |
| 15 |
[GO] |
2022―Feb―17 |
Properties of RBD specific IgG from COVID-19 patients and Sputnik V vaccinated individuals |
LV Generalova, IV Grigoriev, DV Vasina, AP Tkachuk, IS Kruzhkova, LV Kolobukhina, et al. (+2) OA Burgasova, VA Guschin |
| 16 |
[GO] |
2021―Dec―31 |
Factors associated with increase in alcohol consumption during first months of COVID-19 pandemic among online social media users in Russia |
AU Gil, AK Demin |
| 17 |
[GO] |
2021―Oct―19 |
Assessment of COVID-19 clinical course in patients vaccinated with Spitnik V, SARS-CoV-2 S protein RBD domain variation and serum virus neutralizing activity |
LV Kolobukhina, OA Burgasova, IS Kruzhkova, VV Bakalin, LV Generalova, AV Shagaev, et al. (+5) DA Ogarkova, MA Nikiforova, DV Vasina, VA Guschin, SV Smetanina |
| 18 |
[GO] |
2021―Oct―07 |
Analysis of causes of early neonatal mortality during covid-19 pandemic in 2020 in Russia |
UN Tumanova, AI Schegolev, AA Chausov, MP Shuvalova |
| 19 |
[GO] |
2021―Jul―15 |
Estimation SARS-CoV-2 viability in time on experimental surfaces over |
MA Nikiforova, AE Siniavin, EV Shidlovskaya, NA Kuznetsova, VA Guschin |
| 20 |
[GO] |
2021―Jun―30 |
Changes in amino acid profile of cord blood plasma and amniotic fluid of mothers with COVID-19 |
NA Lomova, VV Chagovets, EL Dolgopolova, AV Novoselova, UL Petrova, RG Shmakov, VE Frankevich |
| 21 |
[GO] |
2021―Jun―19 |
Persistence of SARS-CoV-2 in deceased patients and safe handling of infected bodies |
AI Schegolev, UN Tumanova |
| 22 |
[GO] |
2021―Jun―07 |
Changes in blood levels of IL1 family cytokines in patients with essential hypertension after having COVID-19 |
OA Radaeva, AS Simbirtsev, YuA Kostina, MS Iskandiarova, SV Mashnina, DD Bessheynov, et al. (+2) EV Negodnova, VV Kulyapkin |
| 23 |
[GO] |
2021―May―31 |
Emergency surgical care for patients with COVID-19 and tuberculosis coinfection at multispecialty hospital |
MN Reshetnikov, DV Plotkin, ON Zuban, EM Bogorodskaya |
| 24 |
[GO] |
2021―May―03 |
The impact of the novel coronavirus infection COVID-19 on the mother-placenta-fetus system |
NV Nizyaeva, NA Lomova, EL Dolgopolova, UL Petrova, TE Karapetyan, RG Shmakov, VE Frankevich |
| 25 |
[GO] |
2021―Mar―01 |
The importance of determining SARS-CoV-2 N-Ag serodiagnostics for the management of COVID-19 pneumonia in hospital settings |
YuS Lebedin, OV Lyang, AG Galstyan, AV Panteleeva, VV Belousov, DV Rebrikov |
| 26 |
[GO] |
2021―Feb―09 |
The features of HIV and SARS-CoV-2-coinfection in a pandemic |
AF Oleynik, CG Revathy, VH Fazylov |
| 27 |
[GO] |
2020―Dec―30 |
COVID-19 patients’ satisfaction with quality of medical care provided in the form of telemedicine consultations |
NV Polunina, AA Tyazhelnikov, AV Pogonin, EV Kostenko |
| 28 |
[GO] |
2020―Oct―23 |
Difficulties in differential diagnosis of cutaneous manifestations in patients with coronavirus infection |
RT Tairova, TA Gaydina, AS Dvornikov, AD Tazartukova, OV Lyang |
| 29 |
[GO] |
2020―Sep―22 |
Antiviral system of innate immunity: COVID-19 pathogenesis and treatment |
AN Kazimirskii, JM Salmasi, GV Poryadin |
| 30 |
[GO] |
2020―Jul―28 |
Spread of variants with gene N hot spot mutations in russian SARS-CoV-2 isolates |
SA Kiryanov, TA Levina, MYu Kirillov |
| 31 |
[GO] |
2020―Jun―29 |
Diagnosis and treatment of acute surgical diseases in patients with COVID-19 |
VI Vechorko, VD Anosov, BV Silaev |
| 32 |
[GO] |
2020―Jun―26 |
IgM and IgG antibodies against SARS-CoV-2 in neonates born to mothers with COVID-19 |
AA Semeshkin, VI Vechorko, BV Silaev, NN Levchuk, SV Polikarpova, OV Averkov |
| 33 |
[GO] |
2020―Jun―23 |
Immunity to COVID-19 and issues of screening for SARS-Cov-2 antibodies |
NA Mayanskiy |
| 34 |
[GO] |
2020―Jun―03 |
Structure of anxiety associated with СOVID-19 pandemic: the online survey results |
MYu Sorokin, ED Kasyanov, GV Rukavishnikov, OV Makarevich, NG Neznanov, NB Lutova, GE Mazo |
| 35 |
[GO] |
2020―Apr―30 |
On the unpredictability of outcomes of immunotherapy and preventive immunization against COVID-19 |
IV Chebotar, DA Shagin |
| 36 |
[GO] |
2020―Apr―30 |
Strategies of RT-PCR-based assay design and surveillance of SARS-CoV-2 |
NA Kuznetsova, AA Pochtovyy, MA Nikiforova, VA Guschin |
| 37 |
[GO] |
2020―Apr―29 |
Role of ACE2/TMPRSS2 genes regulation by intestinal microRNA isoforms in the COVID-19 pathogenesis |
SA Nersisyan, MYu Shkurnikov, AI Osipyants, VI Vechorko |
| 38 |
[GO] |
2020―Apr―18 |
Possible effects of coronavurus infection (COVID-19) on the cardiovascular system |
VN Larina, MG Golovko, VG Larin |
